BTIG Upgrades Outlook Therapeutics to Buy, Announces $4 Price Target

Benzinga · 1d ago
BTIG analyst Julian Harrison upgrades Outlook Therapeutics (NASDAQ:OTLK) from Neutral to Buy and announces $4 price target.